Pliant Therapeutics
Update in progressPLRX (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing integrin-based therapies for solid tumors. Its lead candidate, PLN-101095, is an oral, small-molecule dual inhibitor of αvβ8 and αvβ1 in Phase 1a/1b. The company also builds a drug discovery platform with a library of over 15,000 integrin-binding molecules aimed at integrin-based target-mediated delivery. Founded in 2015, based in South San Francisco.
Company score
- Sentiment
- -0.09
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.21
- Governance
- -0.10
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.09
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEODr. Bernard Coulie M.B.A., M.D., Ph.D.
- Founded2015
- Employees49
- Websitepliantrx.com
Identifiers
- ISINUS7291391057
- FIGIBBG00C8083N4
- LEI5493002Q5LITR7VHZH02
- CUSIP69912C105
- CIK0001746473